From Amylin Resurrects Obesity Drug, in New Combination with Diabetes Drug Symlin:

amylin1—

Amylin Pharmaceuticals is developing drugs for obesity and diabetes

    

Underwriters and Partners

Connect with Xconomy

• 
• 
• 
• 
• 

Xconomy’s Most Popular

1. Biotech IPOs Start to Show Some Modest Signs of Life
2. ASCO Preview: Eight Cancer Drugs to Watch at the Big Show
3. Hey, Silicon Valley: Wake Up and Smell the Robots
4. Announcing Xconomy’s Napa Summit: Keeping America Growing
5. From MIT Entrepreneur to Tea Party Leader: The Thomas Massie Story

Xconomy on Demand

Did you miss something? Don't despair…

Xconomy offers a number of ways to subscribe for free!

Subscribe Now

• Home
• Privacy/DMCA
• About
• Contact Us
• Archives
• Advertise
• RSS

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.

© 2007-2012, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.

Site produced by Andrew Koyfman with design from Rob Hunter.